PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
Launched by THOMAS JEFFERSON UNIVERSITY · Mar 7, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The EUCLID Trial is studying how a special type of imaging called PET/CT scans can help doctors see if radiation treatment for lung or esophageal cancer is affecting the heart. When patients receive radiation to treat their cancer, sometimes the heart can also receive some radiation, which may change how well it works. This study aims to find out if doctors can use these scans to monitor any changes in heart function before, during, and after radiation therapy.
To join this trial, participants must be at least 18 years old and have a confirmed diagnosis of lung or esophageal cancer. They should expect to sign an informed consent form and be willing to follow the study procedures. It's important that their heart receives a certain amount of radiation during treatment, as determined by their doctor. However, there are some reasons that may prevent someone from participating, such as certain health conditions that affect their ability to undergo the imaging scans. Overall, this study could provide valuable information about protecting heart health in cancer patients undergoing radiation therapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provide signed and dated informed consent form
- • Willing to comply with all study procedures and be available for the duration of the study
- • Male or female, aged \>= 18
- • Life expectancy \>= 3 months as assessed by Radiation Oncologist
- • Mean heart dose estimated by Radiation Oncologist to be \>= 5 Gy (physics dose or biologically equivalent dose)
- • Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer
- • Planned radiation treatment course for management of lung or esophageal cancer \* Both standard and hypofractionation schedules are permitted
- Exclusion Criteria:
- • Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist
- • Palliative radiation doses defined as 20 Gy in 5 fractions
About Thomas Jefferson University
Thomas Jefferson University is a distinguished academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to advancing healthcare through research and education. As a clinical trial sponsor, the university leverages its extensive resources and interdisciplinary expertise to conduct innovative research aimed at improving patient outcomes. With a focus on translational medicine, Thomas Jefferson University collaborates with various stakeholders, including healthcare professionals, industry partners, and regulatory agencies, to ensure the highest standards of scientific rigor and ethical conduct in its clinical trials. The institution is dedicated to fostering a culture of excellence in research, ultimately contributing to the advancement of medical knowledge and the development of novel therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Yevgeniy Vinogradskiy
Principal Investigator
Thomas Jefferson University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials